Browsing by Author "Kara B.Y."

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    What we learned about COVID-19 so far? Notes from underground
    (AVES, 2020) Akyıl F.T.; Karadoğan D.; Gürkan C.G.; Yüksel A.; Arıkan H.; Eyüboğlu T.Ş.; Emiralioğlu N.; Gürsoy T.R.; Şerifoğlu İ.; Töreyin Z.N.; Marim F.; Kara B.Y.; Özakıncı H.; Develi E.; Çakmakçı S.; Küsbeci T.Ç.; Karcıoğlu O.; Gülhan P.Y.; Erçelik M.; Er B.; Ataoğlu Ö.; Polat D.; Kaya İ.; Önyılmaz T.A.; Aydın A.; Kızılırmak D.; Er A.B.; Kılınç M.; Günaydın F.E.; Gürz S.; Karaoğlanoğlu S.; Çelik S.; Esendağlı D.; Toptay H.; Sertçelik Ü.Ö.; Akgün M.
    The novel coronavirus pandemic poses a major global threat to public health. Our knowledge concerning every aspect of COVID-19 is evolving rapidly, given the increasing data from all over the world. In this narrative review, the Turkish Thoracic Society Early Career Taskforce members aimed to provide a summary on recent literature regarding epidemiology, clinical findings, diagnosis, treatment, prevention, and control of COVID-19. Studies revealed that the genetic sequence of the novel coronavirus showed significant identity to SARS-CoV and MERS-CoV. Angiotensin-converting enzyme 2 receptor is an important target of the SARS-CoV-2 while entering an organism. Smokers were more likely to develop the disease and have a higher risk for ICU admission. The mean incubation period was 6.4 days, whereas asymptomatic transmission was reported up to 25 days after infection. Fever and cough were the most common symptoms, and cardiovascular diseases and hypertension were reported to be the most common comorbidities among patients. Clinical manifestations range from asymptomatic and mild disease to severe acute respiratory distress syndrome. Several patients showed typical symptoms and radiological changes with negative RT-PCR but positive IgG and IgM antibodies. Although radiological findings may vary, bilateral, peripherally distributed, ground-glass opacities were typical of COVID-19. Poor prognosis was associated with older age, higher Sequential Organ Failure Assessment score, and high D-dimer level. Chloroquine was found to be effective in reducing viral replication in vitro. Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to be the potential drug candidates in COVID-19 management. Despite these efforts, we still have much to learn regarding the transmission, treatment, and prevention of COVID-19. © 2020 by Turkish Thoracic Society.
  • No Thumbnail Available
    Item
    Turkish Thoracic Society Early Career Members Task Force Group’s Virtual Congress Notes: European Respiratory Society International Congress 2020
    (AVES, 2022) Kızılırmak D.; Karadoğan D.; Yıldırım H.; Akyıl F.T.; Eyüboğlu T.Ş.; Emiralioğlu N.; Sertçelik Ü.Ö.; Günaydın F.E.; Ataoğlu Ö.; Oğuz M.S.; Çakmakcı S.; Özçelik N.; Öncel A.; Fırıncıoğluları A.; Kara B.Y.; Ömer D.; Karaoğlanoğlu S.; Cetin N.; Karakas F.G.; Gurkan C.G.; Marim F.; Önyılmaz T.; Yuluğ D.P.; Öztürk N.A.A.; Güçlü Ö.A.; Küsbeci T.Ç.; Şerifoğlu İ.; Arıkan H.; Töreyin Z.N.; Çelik P.; Akgün M.
    In this article, Early Career Task Force Group members of the Turkish Thoracic Society summarize the European Respiratory Society 2020 virtual congress. Current developments in the field of respiratory diseases were compiled with the addition of sessions specific to coronavirus disease 2019 this year. Almost all of the congress sessions were examined, and the important and striking results of the congress were highlighted. Congress sessions were attended by expert researchers, and the prominent messages of each session were highlighted in short summaries. They were then grouped under relevant titles and ranked in order of meaning and relation. It was finalized by a team of researchers. © Author(s).
  • No Thumbnail Available
    Item
    Picturing asthma in Turkey: results from the Turkish adult asthma registry
    (Taylor and Francis Ltd., 2023) Celik G.E.; Aydin O.; Gokmen D.; Koycu Buhari G.; Celebi Sozener Z.; Gemicioglu B.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Koca Kalkan I.; Uysal M.A.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Oner Erkekol F.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Oguzulgen I.K.; Basyigit I.; Baris S.A.; Yilmazel Ucar E.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Turk M.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Polat Yulug D.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Tas Gulen S.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Arslan B.; Cetin G.P.; Soyyigit S.; Kara B.Y.; Pasaoglu Karakis G.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Sevinc C.; Omeroglu Simsek G.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.
    Introduction: National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry for patients with asthma aiming to take a snapshot of our patients, thereby assigning the unmet needs and niche areas of intervention. Methods: Case entries were performed between March 2018 and March 2022. A web-based application was used to record data. Study outcomes were demographic features, disease characteristics, asthma control levels, and phenotypes. Results: The registry included 2053 patients from 36 study centers in Turkey. Female subjects dominated the group (n = 1535, 74.8%). The majority of the patients had allergic (n = 1158, 65.3%) and eosinophilic (n = 1174, 57.2%) asthma. Six hundred nineteen (32.2%) of the patients had obese asthma. Severe asthma existed in 670 (32.6%) patients. Majority of cases were on step 3–5 treatment (n: 1525; 88.1%). Uncontrolled asthma was associated with low educational level, severe asthma attacks in the last year, low FEV1, existence of chronic rhinosinusitis and living in particular regions. Conclusion: The picture of this registry showed a dominancy of middle-aged obese women with moderate-to-severe asthma. We also determined particular strategic targets such as low educational level, severe asthma attacks, low FEV1, and chronic rhinosinusitis to decrease uncontrolled asthma in our country. Moreover, some regional strategies may also be needed as uncontrolled asthma is higher in certain regions. We believe that these data will guide authorities to reestablish national asthma programs to improve asthma service delivery. © 2023 Taylor & Francis Group, LLC.
  • No Thumbnail Available
    Item
    Socioeconomic status has direct impact on asthma control: Turkish adult asthma registry
    (John Wiley and Sons Inc, 2025) Arslan B.; Türk M.; Hayme S.; Aydin Ö.; Gokmen D.; Buhari G.K.; Sozener Z.C.; Gemicioglu B.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Kalkan I.K.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Erkekol F.O.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Oguzulgen I.K.; Basyigit I.; Baris S.A.; Ucar E.Y.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Yulug D.P.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Cetin G.P.; Soyyigit S.; Kara B.Y.; Karakis G.P.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Sevinc C.; Simsek G.O.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Celik G.E.; Uysal M.A.
    Background: Asthma is one of the most common causes of chronic respiratory disease, and countries with low socioeconomic status have both a high prevalence of asthma and asthma-related death. Objective: In this study, we aimed to determine socioeconomic levels of asthmatic patients according to a national database and investigate the effects of social markers on disease control in our region. Methods: This is an analysis of data from 2053 adult asthma patients from a multicentre chart study in Turkey. Socioeconomic status (SES) data were collected from questionnaires and this form was sent to the patients via e-mail. Parameters related to social status and poor disease control were analyzed. Results: Illiteracy (OR:2.687 [95% CI: 1.235–5.848]; p = 0.013) and lower household income (OR:1,76 [95% CI: 1.002–3.09]; p = 0.049) were found as independent risk factors for hospitalization in the multivariate logistic regression analysis. Therewithal, being aged between 40 and 60 (OR: 1.435 [95% CI: 1.074–1.917]; p = 0.015), illiteracy (OR: 2.188 [95% CI: 1.262–3.795]; p = 0.005) and being employed (OR: 1.466 [95% CI: 1.085–1.847]; p = 0.011) were considered as independent risk factors for systemic corticosteroid use at least 3 days within last 1 year. Conclusion: As a result of our national database, education level, household income and working status briefly socioeconomic status have impacts on asthma control. Identification of social markers in asthma and better recognition of risk factors based on the population gives us clues to provide better asthma control in the future. © 2025 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
  • No Thumbnail Available
    Item
    Trends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry
    (Exon Publications, 2025) Beyaz Ş.; Erdinç M.; Hayme S.; Aslan A.F.; Aydın Ö.; Gökmen D.; Buhari G.K.; Sözener Z.Ç.; Gemicioğlu B.; Bulut İ.; Örçen C.; Özdemir S.K.; Keren M.; Damadoğlu E.; Yakut T.; Kalpaklıoğlu A.F.; Baccıoğlu A.; Yalım S.A.; Yılmaz İ.; Kalkan İ.K.; Uysal M.A.; Niksarlıoğlu E.Y.Ö.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayc S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Göksel Ö.; Karaoğlanoğlu S.; Erkekol F.Ö.; Isık S.R.; Yıldız F.; Yavuz Y.; Karadoğan D.; Bozkurt N.; Şeker Ü.; Oğuzülgen İ.K.; Başyiğit İ.; Barış S.A.; Uçar E.Y.; Erdoğan T.; Polatlı M.; Ediger D.; Günaydın F.E.; Türk M.; Pür L.; Katran Z.Y.; Sekibağ Y.; Aykaç E.F.; Mungan D.; Gül Ö.; Cengiz A.; Akkurt B.; Özden Ş.; Demir S.; Ünal D.; Can A.; Gümüşburun R.; Boğatekin G.; Akten H.S.; İnan S.; Öğüş A.C.; Kavas M.; Yuluğ D.P.; Çakmak M.E.; Kaya S.B.; Alpagat G.; Özgür E.S.; Uzun O.; Gülen Ş.T.; Pekbak G.; Kızılırmak D.; Havlucu Y.; Dönmez H.; Arslan B.; Çetin G.P.; Soyyiğit Ş.; Kara B.Y.; Karakış G.P.; Dursun A.B.; Kendirlinan R.; Öztürk A.B.; Sevinç C.; Şimşek G.Ö.; Abadoğlu Ö.; Çerçi P.; Yücel T.; Yorulmaz İ.; Tezcaner Z.Ç.; Tatar E.Ç.; Süslü A.E.; Özer S.; Dursun E.; Yorgancıoğlu A.; Çelik G.E.
    Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.76% (n = 1268; mean age: 46.2 ± 14.3 years), predominantly females (~76%), received montelukast. Montelukast users showed higher rates of allergic rhinitis (P < 0.001), hyper-sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) (P = 0.008), and chronic rhinosi-nusitis (P = 0.008). Montelukast group also had higher atopy and total IgE levels and tended to be more eosinophilic. Montelukast was commonly preferred in allergic, eosinophilic, NSAID-exacerbated respiratory disease, and severe asthma phenotypes (P < 0.001). Patients receiving Steps 4 and 5 treatments are more likely to be prescribed montelukast (P < 0.001). Montelukast usage was higher among patients with uncontrolled asthma [ACT< 20 (OR:1.29, 95%CI:1.052–1.582, P = 0.014)]. In addition, logistic regression analyses identified the main factors associated with increased montelukast use as; female gender (OR:1.33, 95%CI:1.041–1.713, P = 0.02), presence of atopy (OR:1.46, 95%CI:1.157–1.864, P = 0.002), comorbid allergic rhinitis (OR:2.12, 95%CI:1.679–2.293, P < 0.001), and severe asthma (OR:2.18, 95%CI:1.712–2.784, P < 0.001). These findings reveal that montelukast use is prevalent among asthma patients, particularly in females, middle-aged adults, and those with comorbid allergic rhinitis, uncontrolled asthma, or specific asthma phenotypes, underscoring the factors that influence its prescription in asthma management. © 2025 Codon Publications.
  • No Thumbnail Available
    Item
    Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry
    (W.B. Saunders Ltd, 2025) Gemicioglu B.; Gokmen D.; Can A.; Sevinc C.; Oguzulgen I.K.; Soyyigit S.; Yakut T.; Havlucu Y.; Aydin O.; Buhari G.K.; Sozener Z.C.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Kalkan I.K.; Uysal M.A.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Erkekol F.O.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Basyigit I.; Baris S.A.; Ucar E.Y.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Turk M.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Yulug D.P.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Donmez H.; Arslan B.; Cetin G.P.; Kara B.Y.; Dursun A.B.; Karakis G.P.; Kendirlinan R.; Ozturk A.B.; Simsek G.O.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Çelik G.E.
    Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians’ preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics. Patients’ characteristics and disease profiles were analyzed to identify factors associated with the prescription of add-on LAMA across the entire cohort. A comparative analysis was performed among three groups: MART (ICS/formoterol as a maintenance and reliever therapy) plus LAMA, Conventional (ICS/LABA as a maintenance and short-acting beta agonist as reliever) plus LAMA and Triple (ICS/LABA/LAMA single inhaler). LAMAs were added to ICS/LABA in 11.7 % of patients in the national registry. Logistic regression analysis revealed that older age, low FEV1 (%), Asthma Control Test (ACT) scores less than 20, and severe exacerbation were the main factors influencing the initiation of LAMA in our registry. However, demographic characteristics of asthma, control status, pulmonary function test results were similar among the three groups of LAMA users (p > 0.05). Physicians used LAMAs without phenotyping based on allergic status or eosinophil levels (p > 0.05). Mepolizumab was added after LAMA in all patients, while omalizumab was initiated before LAMA in 16.9 % of the patients receiving LAMA along with biologics. Add-on LAMAs were predominantly prescribed for older, uncontrolled, and exacerbated asthma patients with low FEV1. © 2024 Elsevier Ltd